SCHEMBL7787482

SCHEMBL7787482

CCc1ccc(Br)cc1CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
EDNRB P24530 2/20 0.37
EDNRA P25101 2/20 0.37
HSP90AA1 P07900 1/20 0.37
TLR9 Q9NR96 1/20 0.37
S100A4 P26447 1/20 0.37
PRNP P04156 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10383147 0.89 SMN1; SMN2 (0.38) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL1581441 0.88 SMN1; SMN2 (0.40) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL14389060 0.86 SMN1; SMN2 (0.39) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL15835000 0.86 EDNRB (0.40) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL12721174 0.86 SMN1; SMN2 (0.39) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL23275220 0.86 SMN1; SMN2 (0.39) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL4477052 0.86 CYP2A6 (0.43) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL14389056 0.86 SMN1; SMN2 (0.39) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL20561878 0.86 SMN1; SMN2 (0.39) GABRA1GABRB2SMN1; SMN2LMNAHPGD
SCHEMBL1581656 0.86 PTGDR2 (0.47) GABRA1GABRB2SMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240074301-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-02-29 US disclosed
EP-3611165-B1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) 2023-08-16 EP disclosed
WO-2023088420-A1 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER Chengdu Anticancer Bioscience, Ltd. (CN) 2023-05-25 WO disclosed
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-10781211-B2 Spirocycle compounds and methods of making and using same LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2020-09-22 US disclosed
EP-3611165-A1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT Mitsui Chemicals Agro, Inc. (JP) 2020-02-19 EP disclosed
US-10030020-B2 Spirocycle compounds and methods of making and using same ABIDE THERAPEUTICS, INC. (US) 2018-07-24 US disclosed
US-20170327500-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2017-11-16 US disclosed
EP-3222619-A1 CYCLIC PROTEIN TYROSINE KINASE INHIBITORS Bristol-Myers Squibb Holdings Ireland (CH) 2017-09-27 EP disclosed
CN-103649102-A Diarylsulphid backbone containing photolabile protecting groups HOFFMANN LA ROCHE 2014-03-19 CN disclosed
WO-2013044865-A1 OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING 山东轩竹医药科技有限公司 (CN) 2013-04-04 WO disclosed
US-20090298894-A1 AMINO ACID COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2009-12-03 US disclosed
EP-1150970-A1 (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Sanofi-Aventis (FR) 2001-11-07 EP disclosed
WO-2000047572-A1 (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SANOFI-SYNTHELABO (FR) 2000-08-17 WO disclosed
US-4052508-A TRANQUILIZER, MUSCLE RELAXANT, ANTICONVULSANT, ANTIPARKINSON MERCK & CO., INC. (US) 1977-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10781211-B2 Spirocycle compounds and methods of making and using same ABHD6, ABHD16A, ACSL6 GABRA1 4077/4885GABRB2 4341/4885SMN1; SMN2 1888/4885
US-20240074301-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES ICOSLG, OCIAD2, OSBP GABRA1 3198/4885GABRB2 2734/4885SMN1; SMN2 4332/4885
US-20170327500-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, ACSL6 GABRA1 4077/4885GABRB2 4341/4885SMN1; SMN2 1888/4885
US-20090298894-A1 AMINO ACID COMPOUNDS S1PR1, S1PR2, S1PR5 GABRA1 425/4885GABRB2 1069/4885SMN1; SMN2 2780/4885
US-10030020-B2 Spirocycle compounds and methods of making and using same ABHD6, ABHD16A, ACSL6 GABRA1 4077/4885GABRB2 4341/4885SMN1; SMN2 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.